# EDGAR Filing Document

**Accession Number:** 0001715925
**File Stem:** 0000950170-25-085146
**Filing Date:** 2025-6
**Character Count:** 8985
**Document Hash:** 2f1e8bcb2a189ed060740af8d0ac6fd9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-085146.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0000950170-25-085146

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250612

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ImmunoPrecise Antibodies Ltd.
- **CENTRAL INDEX KEY:** 0001715925
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39530
- **FILM NUMBER:** 251041725

**BUSINESS ADDRESS:**
- **STREET 1:** INDUSTRIOUS, 823 CONGRESS AVE, SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
- **BUSINESS PHONE:** 6048060626

**MAIL ADDRESS:**
- **STREET 1:** INDUSTRIOUS, 823 CONGRESS AVE, SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**Form 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the month of **<u>June, 2025</u>**.

Commission File Number: **<u>001-39530</u>**

 **<u>ImmunoPrecise Antibodies Ltd.</u>** 

**Industrious 823 Congress Ave Suite 300 Austin, Texas 78701**

(Address of principal executive office)

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;99.1<br>| [<u>Press Release dated June 12, 2025</u>](ipa-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMMUNOPRECISE ANTIBODIES LTD.** | **IMMUNOPRECISE ANTIBODIES LTD.** |
| Date: June 12, 2025 |  |  |
|  | By: | /s/ Jennifer Bath<br>|
|  | Name: | Jennifer Bath |
|  | Title: | President and Chief Executive Officer |

---

------

## Exhibit 99.1

**AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies** <br>

**Breakthrough in AI-powered drug discovery validates HYFT®-driven peptide design, with broad potential across multiple therapeutic areas** 

**AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA)**, a leader in AI-powered drug discovery and biotherapeutics, today announced compelling *in vitro* results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The *in vitro* analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings.

Crucially, the sequences were not discovered by chance. They were designed using HYFT-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets.

With GLP-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that AI can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same HYFT-driven approach.

"This is not a one-off success," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "We've demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. It represents a foundational shift in how therapeutics are discovered. The same LENS<sup>ai</sup>-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with GLP-1."

IPA is now considering two complementary preclinical paths for its lead GLP-1 candidates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance

------

durability, patient compliance, and ease of administration.

The sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches.

The significance of this breakthrough extends far beyond GLP-1. The same AI framework and HYFT-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance.

This announcement follows IPA's recent success with AI-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases.

**About ImmunoPrecise Antibodies Ltd.** 

<br>ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT™ technology and LENS<sup>ai</sup> platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the LENS<sup>ai</sup> and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery methods; the continued development and potential preclinical or clinical progression of IPA's AI-designed GLP-1 peptide program; the feasibility of next-generation delivery strategies; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas.

Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of AI-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those

------

expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at <u>www.sedarplus.ca</u> and EDGAR profile at <u>www.sec.gov/edgar</u>). Should any of these risks materialize, actual results could vary significantly from those currently anticipated.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.

**Investor Relations Contact** 

<br> Louie Toma <br> Managing Director, CORE IR <br> <u>investors@ipatherapeutics.com</u> 

**Source:** ImmunoPrecise Antibodies Ltd.

------